| Bid | 21.01 |
| Market Cap | 23.83B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -25.31 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 21.05 |
| Volume | 6,212,302 |
| Avg. Volume (20D) | 8,930,157 |
| Open | 20.61 |
| Previous Close | 20.44 |
| Day's Range | 20.41 - 21.02 |
| 52-Week Range | 10.83 - 22.80 |
| Beta | undefined |
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and cr...
Analyst Forecast
According to 7 analyst ratings, the average rating for TEVA stock is "Strong Buy." The 12-month stock price forecast is $21, which is a decrease of -0.02% from the latest price.
Next Earnings Release
Analysts project revenue of $4.16B, reflecting a -6.66% YoY shrinking and earnings per share of 0.72, making a -28.00% decrease YoY.
4 weeks ago · https://thefly.com
Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIGBTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in dev...
